Abstract: A peptide or peptide derivative comprising: (i) WDLYFEIVW (SEQ ID NO: 1); or (ii) a variant amino acid sequence comprising one, two, three or four L-amino acid substitutions in WDLYFEIVW (SEQ ID NO: 1); or (iii) the retro-inverso variant of the peptide or peptide derivative of either one of parts (i) and (ii), wherein said peptide or peptide derivative has procoagulant activity. A peptide or peptide derivative comprising: (i) an amino acid sequence comprising imfwydcye; or (ii) a variant amino acid sequence comprising one, two, three, four, five or six amino acid substitutions in imfwydcye, wherein said peptide or peptide derivative has procoagulant activity.
Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, an identify a TFPI-binding compound.
Type:
Application
Filed:
January 14, 2019
Publication date:
May 9, 2019
Applicants:
BAXALTA GMBH, BAXALTA INCORPORATED
Inventors:
Michael Dockal, Rudolf Hartmann, Markus Fries, Friedrich Scheiflinger, Hartmut Ehrlich, Ulrich Reineke, Frank Osterkamp, Thomas Polakowski
Abstract: The present specification discloses methods of characterizing a population of particles using a particle analyzer. Particles may be characterized by size, absolute number, whether the particle is non-proteinaceous or proteinaceous, whether a proteinaceous particle has or lacks a certain physical property, or any combination thereof.
Type:
Grant
Filed:
January 11, 2013
Date of Patent:
April 30, 2019
Assignees:
Baxalta Incorporated, Baxalta GmbH
Inventors:
Mantas Malisauskas, Christian Lubich, Thomas Prenninger, Birgit Reipert
Abstract: The invention relates to a holder, in particular a cleaning device, for receiving at least one preferably elongate sample container, in particular a cuvette, which has an opening and a bottom opposite the opening in a longitudinal direction and closing the sample container, for cleaning such a sample container, wherein the holder is provided with a first element for at least partially abutting in the longitudinal direction against an edge of the opening of the sample container, the edge facing towards the longitudinal direction, wherein the first element has a passage which is configured in such a way that it at least partially overlaps with the opening of the sample container when the sample container is received, and which is configured, when the sample container is received, to introduce and discharge fluid through the opening for cleaning the sample container, and has a second element, which is essentially opposite the first element in the longitudinal direction, for at least partially abutting in the lon
Abstract: The present invention relates to a proteinaceous construct comprising plasmatic or recombinant factor VIIa (FVIIa) or biologically active derivatives thereof, which are bound to a carbohydrate moiety comprising 1-4 sialic acid units, wherein the in vivo half-life of the proteinaceous construct is substantially prolonged in the blood of a mammal, as compared to the in vivo half-life of a FVIIa molecule not bound to a carbohydrate moiety. The invention also provides a method for controlling bleeding in a mammal having a bleeding disorder due to functional defects or deficiencies of FVIIa, FVIII, or FIX. The invention also provides a method for controlling bleeding in a mammal during surgery or trauma.
Type:
Grant
Filed:
November 19, 2015
Date of Patent:
April 9, 2019
Assignees:
Baxalta Incorporated, Baxalta GmbH
Inventors:
Peter Turecek, Juergen Siekmann, Friedrich Scheiflinger, Michel Canavaggio
Abstract: The present invention relates to formulations of ADAMTS13 with enhanced or desirable properties. As such, the invention provides liquid and lyophilized formulations of ADAMTS13 that are suitable for pharmaceutical administration. Among other aspects, the present invention also provides methods of treating various diseases and conditions related to VWF and/or ADAMTS13 dysfunction in a subject. Also provided herein are kits comprising ADAMTS13 formulations useful for the treatment of various diseases and conditions.
Type:
Grant
Filed:
February 28, 2018
Date of Patent:
March 26, 2019
Assignees:
Baxalta Incorporated, Baxalta GmbH
Inventors:
Peter Matthiessen, Peter L. Turecek, Hans-Peter Schwarz
Abstract: This invention relates to a pharmaceutical composition having thrombolytic activity comprising ADAMTS13, and to methods for treating or preventing a disorder associated with the formation and/or the presence of one or more thrombus and to methods of disintegrating one or more thrombus in a patient in need thereof. Furthermore, the invention relates to the use of a pharmaceutically effective amount of ADAMTS13 for the preparation of a pharmaceutical composition for treating or preventing a disorder associated with the formation or the presence of one or more thrombus and for disintegrating one or more thrombus in a patient in need thereof.
Type:
Grant
Filed:
January 22, 2013
Date of Patent:
March 19, 2019
Assignees:
Baxalta Incorporated, Baxalta GmbH, Children's Medical Center Corporation
Inventors:
Denisa D. Wagner, Anil Kumar Chauhan, Friedrich Scheiflinger, Barbara Plaimauer
Abstract: Long-term stable pharmaceutical formulations of lyophilized recombinant von-Willebrand Factor (rVWF) and methods for making and administering said formulations are described.
Type:
Grant
Filed:
November 12, 2015
Date of Patent:
March 19, 2019
Assignees:
Baxalta Incorporated, Baxalta GmbH
Inventors:
Kurt Schnecker, Eva Haidweger, Peter Turecek
Abstract: The present invention relates to animal protein-free cell culture media comprising polyamines and a plant- and/or yeast-derived hydrolysate. The invention also relates to animal protein-free culturing processes, wherein cells can be cultivated, propagated and passaged without adding supplementary animal proteins in the culture medium. These processes are useful in cultivating cells, such as recombinant cells or cells infected with a virus, and for producing biological products by cell culture processes.
Type:
Application
Filed:
October 29, 2018
Publication date:
March 14, 2019
Applicants:
Baxalta Incorporated, Baxalta GmbH
Inventors:
Leopold Grillberger, Manfred Reiter, Wolfgang Mundt, Friedrich Dorner
Abstract: Described herein is a chemostat-like continuous cell culture system that combines certain advantages of perfusion open systems and chemostat open systems to improve the culturing of mammalian cells, e.g., genetically modified cells, particularly in serum-free or chemically-defined media. The continuous culture system described herein involves culturing mammalian cells in a continuous cell culture system, which comprises a cell retention device, wherein the cell culture system has a dilution rate (D) of less than about 2 d?1, and a cell density of less than about 2×107 cell/mL.
Type:
Grant
Filed:
April 12, 2017
Date of Patent:
March 5, 2019
Assignees:
Baxalta GmbH, Baxalta Incorporated
Inventors:
Leopold Grillberger, Manfred Reiter, Daniel Fleischanderl
Abstract: The present invention relates to a method for purifying a Factor VIII (FVIII) subspecies from a composition comprising FVIII, said method comprising an anion exchange chromatography step, a size exclusion chromatography step, and a concentration step. The invention also relates to a composition comprising a purified FVIII subspecies.
Type:
Application
Filed:
June 22, 2018
Publication date:
February 28, 2019
Applicants:
Baxalta Incorporated, Baxalta GmbH
Inventors:
Meinhard HASSLACHER, Martin FEICHTINGER, Philipp M. BÄRNTHALER, Christa MAYER, Birgit REIPERT, Mantas MALISAUSKAS, Julia ANZENGRUBER
Abstract: The present invention provides novel methods for reducing the serine protease and/or serine protease zymogen content of a plasma-derived protein composition. Also provided are methods for manufacturing plasma-derived protein compositions having reduced serine protease and\or serine protease zymogen content. Among yet other aspects, the present invention provides aqueous and lyophilized compositions of plasma-derived proteins having reduced serine protease and/or serine protease zymogen content. Yet other aspects include methods for treating, managing, and/or preventing a disease comprising the administration of a plasma-derived protein composition having a reduced serine protease or serine protease zymogen content.
Type:
Grant
Filed:
June 9, 2017
Date of Patent:
February 19, 2019
Assignees:
Baxalta Incorporated, Baxalta GmbH
Inventors:
Wolfgang Teschner, Hans-Peter Schwarz, Ruth Madlener, Sonja Svatos, Azra Pljevljakovic, Alfred Weber
Abstract: The invention generally relates to methods of measuring cleaved von Willebrand factor (VWF) fragments. More specifically, the invention relates to methods of measuring the ability of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) to cleave VWF in vivo. The invention also relates to methods of using various animal models which demonstrate ADAMTS13 activity similar to that of a human. The invention further relates to methods of measuring the cleavage products of rVWF in mammals, particularly in humans and in human plasma.
Type:
Grant
Filed:
November 7, 2016
Date of Patent:
February 19, 2019
Assignees:
BAXALTA INCORPORATED, BAXALTA GMBH
Inventors:
Katalin Varadi, Hanspeter Rottensteiner, Peter Turecek, Hans-Peter Schwarz, Jutta Schreiner
Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, an identify a TFPI-binding compound.
Type:
Grant
Filed:
December 9, 2016
Date of Patent:
February 12, 2019
Assignees:
Baxalta GmbH, Baxalta Incorporated
Inventors:
Michael Dockal, Rudolf Hartmann, Markus Fries, Friedrich Scheiflinger, Hartmut Ehrlich, Ulrich Reineke, Frank Osterkamp, Thomas Polakowski
Abstract: The present invention relates to a method for the purification of divalent cation binding proteins with high purity on an anion exchange resin material, to divalent cation binding proteins obtainable by said method, and to a kit comprising means for carrying out said method.
Type:
Grant
Filed:
April 29, 2011
Date of Patent:
February 12, 2019
Assignees:
Baxalta Incorporated, Baxalta GmbH
Inventors:
Artur Mitterer, Meinhard Hasslacher, Christian Fiedler
Abstract: The present disclosure provides, among other aspects, codon-altered polynucleotides encoding Factor VIII variants for expression in mammalian cells. In some embodiments, the disclosure also provides mammalian gene therapy vectors and methods for treating hemophilia A.
Type:
Grant
Filed:
November 11, 2016
Date of Patent:
January 29, 2019
Assignees:
Baxalta Incorporated, Baxalta GmbH
Inventors:
Falko-Günter Falkner, Franziska Horling, Johannes Lengler, Hanspeter Rottensteiner, Friedrich Scheiflinger
Abstract: The present disclosure provides, among other aspects, codon-altered polynucleotides encoding Factor VIII variants for expression in mammalian cells. In some embodiments, the disclosure also provides mammalian gene therapy vectors and methods for treating hemophilia A.
Type:
Grant
Filed:
November 11, 2016
Date of Patent:
January 29, 2019
Assignees:
Baxalta Incorporated, Baxalta GmbH
Inventors:
Falko-Günter Falkner, Franziska Horling, Johannes Lengler, Hanspeter Rottensteiner, Friedrich Scheiflinger
Abstract: The present invention relates a method for incubating liquids, to a method for preparing a biopharmaceutical drug, and to a device for the preparation of a biopharmaceutical drug.
Type:
Application
Filed:
July 10, 2018
Publication date:
January 24, 2019
Applicants:
Baxalta Incorporated, Baxalta GmbH
Inventors:
Nikolaus HAMMERSCHMIDT, Jure SENCAR, Alois JUNGBAUER, Duarte Lima MARTINS
Abstract: The present disclosure provides, among other aspects, improved methods for the manufacture of Factor H compositions from plasma precipitation fractions. In some aspects, the methods include an improved process step for extracting Factor H from a plasma precipitate fraction with reduced co-extraction of amidolytic activities. In other aspects, the methods include a heat treatment step for reducing impurities, such as amidolytic enzymes, from a Factor H composition. In yet other aspects, the methods include improved anion exchange, heparin affinity, and/or mixed mode chromatographic enrichment of Factor H. In still other aspects, the improved methods include a combination of the individual improved process steps disclosed herein.
Type:
Grant
Filed:
March 14, 2014
Date of Patent:
January 22, 2019
Assignees:
Baxalta Incorporated, Baxalta GmbH
Inventors:
Ruth Madlener, Wolfgang Teschner, Hans-Peter Schwarz, Sonja Svatos, Azra Pljevljakovic, Lena Nitsch
Abstract: The present invention provides, among other aspects, methods and compositions for treating a central nervous system (CNS) disorder by delivering a therapeutically effective amount of a composition of pooled human immunoglobulin G (IgG) to the brain via intranasal administration of the composition directly to the olfactory epithelium of the nasal cavity. In particular, methods and compositions for treating Alzheimer's disease are provided.
Type:
Grant
Filed:
October 26, 2016
Date of Patent:
December 4, 2018
Assignees:
Baxalta Incorporated, Baxalta GmbH
Inventors:
William H. Frey, Leah Ranae Bresin Hanson, Sharon Pokropinski, Francisco M. Rausa